Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 12/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.39 |
| ▸ | BCKDK | O14874 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | PTGDR | Q13258 | 5/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.37 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4191120 | 0.83 | AKR1C2 (0.48) | TSHRAKR1C3AKR1C2PTGS1 | |
| SCHEMBL4191239 | 0.82 | POLB (0.46) | MTNR1AMTNR1BTSHR | |
| SCHEMBL4186278 | 0.81 | MTNR1A (0.34) | PTGDR2MTNR1AMTNR1BBCKDK | |
| SCHEMBL4180054 | 0.81 | MCL1 (0.43) | PTGS2 | |
| SCHEMBL4191256 | 0.81 | KDM4E (0.41) | MTNR1AMTNR1BTSHR | |
| SCHEMBL4472382 | 0.80 | KDM4E (0.39) | MTNR1AMTNR1BBCKDKTSHR | |
| SCHEMBL4342850 | 0.79 | CMA1 (0.41) | PTGDR2MTNR1AMTNR1BBCKDKPTGS1 | |
| SCHEMBL4480632 | 0.79 | MTNR1A (0.34) | PTGDR2MTNR1AMTNR1BTSHR | |
| SCHEMBL4193966 | 0.79 | POLB (0.43) | TSHR | |
| SCHEMBL4189697 | 0.77 | KDM4E (0.35) | PTGDR2MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576122-B2 | Ophthalmic compositions for treating ocular hypertension | MERCK & CO. INC. (US) | 2009-08-18 | — | — | US | disclosed |
| EP-1664011-A4 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO INC (US) | 2009-02-25 | — | — | EP | disclosed |
| US-20080287489-A1 | Ophthalmic compositions for treating ocular hypertension | MERCK SHARP & DOHME CORP. | 2008-11-20 | — | — | US | disclosed |
| US-20060276504-A1 | Ophthalmic compositions for treating ocular hypertension | MERCK SHARP & DOHME CORP. | 2006-12-07 | — | — | US | disclosed |
| EP-1664011-A2 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | Merck & Co., Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005020917-A2 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO., INC. (US) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276504-A1 | Ophthalmic compositions for treating ocular hypertension | KCNH2, KCNJ11, KCNN1 | PTGDR2 384/4885MTNR1A 424/4885MTNR1B 356/4885 |
| US-20080287489-A1 | Ophthalmic compositions for treating ocular hypertension | KCNH2, KCNH3, KCNJ11 | PTGDR2 380/4885MTNR1A 460/4885MTNR1B 347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.